Market Place
Sourcing Support
Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children
04 Dec 2024 //
GLOBENEWSWIRE
Teva touts first CGRP success in Phase III paediatric migraine prevention study
19 Jul 2024 //
BUSINESSWIRE
Teva`s AJOVY® Effective, Safe For Migraine Prevention In China
11 Apr 2024 //
BUSINESSWIRE
New Post Hoc Phase 3 Data Analysis Shows AJOVYReduced Migraine Attacks
06 Dec 2023 //
BUSINESSWIRE
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks
17 Oct 2023 //
BUSINESSWIRE
US judge overturns Eli Lilly`s $176.5 million loss in Teva patent case
27 Sep 2023 //
REUTERS
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab)
30 Jun 2023 //
BUSINESSWIRE
Teva to Present Data at the 2023 Scientific Meeting Demonstrating AJOVY
15 Jun 2023 //
BUSINESSWIRE
Teva leans on Ajovy and Austedo as revenues sink
08 Feb 2023 //
FIERCE PHARMA
Teva walks away from PhRMA after similar move by AbbVie
04 Feb 2023 //
FIERCE PHARMA
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY
18 Nov 2022 //
PRESS RELEASE
Studies Show Effectiveness of AJOVY for Treatment of Migraine
08 Sep 2022 //
BUSINESSWIRE
Teva Announces Promising Interim Results From Its Study PEARL, About AJOVY
25 Jun 2022 //
BIOSPACE
New Real-World Data Evaluating AJOVY Injection Use in Migraine
09 Jun 2022 //
BUSINESSWIRE
Teva to Present New Analyses of AJOVY Injection and AUSTEDO Tablets at 2022 AAN
01 Apr 2022 //
BUSINESSWIRE
Teva Canada Welcomes Public Drug Plan Reimbursement & NIHB Program
02 Mar 2022 //
BUSINESSWIRE
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection
30 Sep 2021 //
BUSINESSWIRE
Teva Pharms Usa`s Biological Fremanezumab-Vfrm Receives Approval In US
24 Sep 2021 //
FDA
Teva`s Ajovy can`t find solid win against oral migraine rivals
09 Sep 2021 //
FIERCEPHARMA
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days
30 Aug 2021 //
BUSINESSWIRE
New Data Supporting the Safety and Efficacy Profile of AJOVY
21 Jun 2021 //
BUSINESSWIRE
New data supporting the safety and efficacy profile of AJOVY
21 Jun 2021 //
BUSINESSWIRE
First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection
15 Sep 2020 //
BIOSPACE
Teva Canada announces product availability of AJOVY
19 Aug 2020 //
CANADIANMANUFACTURING
Teva`s Ajovy launch gains steam after autoinjector rollout
10 Aug 2020 //
FIERCE PHARMA
Teva Announces New Drug Application Filing in Japan for AJOVY® (fremanezumab)
29 Jul 2020 //
PRESS RELEASE
UK launch for Ajovy injector pen
20 Jul 2020 //
PHARMATIMES
Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection
15 Jun 2020 //
BUSINESSWIRE
NICE publishes final guidance backing Teva`s Ajovy for migraine
03 Jun 2020 //
PHARMATIMES
Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE®
22 May 2020 //
BUSINESSWIRE
Teva bails on price-fixing deal talks with the feds: report
19 May 2020 //
FIERCE PHARMA
New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO®
01 May 2020 //
BUSINESSWIRE
Teva Canada Announces the Launch of AJOVY™ For the Treatment of Migraine
29 Apr 2020 //
BUSINESSWIRE
Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm)
27 Apr 2020 //
BUSINESSWIRE
U.S. court rules for Teva in migraine patent dispute with Eli Lilly
02 Apr 2020 //
REUTERS
VBI Vaccines Appoints Damian Braga to Board of Directors
12 Mar 2020 //
BUSINESSWIRE
Teva`s Ajovy scores backing from England`s cost watchdogs
12 Mar 2020 //
FIERCE PHARMA
Teva’s weak pipeline hit by Tourette’s drug trial failure
21 Feb 2020 //
PMLIVE
Global cutbacks done, Teva aims to grow with Ajovy, Austedo
12 Feb 2020 //
FIERCE PHARMA
Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab)
03 Feb 2020 //
YAHOO
Teva`s Ajovy finally wins autoinjector nod. Will it help?
30 Jan 2020 //
FIERCE PHARMA
NCCN Oncology Research Program to Oversee Trials the FGFR Inhibitor Futibatinib
27 Jan 2020 //
PR NEWSWIRE
Amgen`s Aimovig, under fire from Lilly, loses grip on CGRP share
05 Sep 2019 //
FIERCE PHARMA
Teva’s CGRP-Inhibitor Reduced Monthly Migraine Days in Late-Stage Trial
21 Aug 2019 //
BIOSPACE
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
11 Jul 2019 //
FIERCE PHARMA
Lilly enlists patients to raise cluster headache awareness
26 Jun 2019 //
FIERCE PHARMA
Lilly`s scored its cluster headache nod for Emgality
05 Jun 2019 //
FIERCE PHARMA
Teva cans Ajovy cluster headache trial, clearing path for Lilly
24 Apr 2019 //
FIERCE PHARMA
Teva stops testing its migraine drug as cluster headache treatment
24 Apr 2019 //
REUTERS
Teva Announces Update on Fremanezumab Clinical Development
23 Apr 2019 //
BUSINESSWIRE
Teva’s migraine injection approved in Europe
04 Apr 2019 //
PMLIVE
Teva`s Ajovy injection secures EU approval for the prevention of migraine
02 Apr 2019 //
PHARMAFILE
European approval for Teva’s migraine drug Ajovy
02 Apr 2019 //
PHARMA TIMES
India’s generic drug maker Glenmark draws up a US-based branded drugs unit
15 Feb 2019 //
ENDPTS
Teva set to shed 11 manufacturing sites in 2019
14 Feb 2019 //
BIOPHARMA DIVE
Teva CEO: `Content` with 2/3 access of payers for migraine drug Ajovy
14 Feb 2019 //
REUTERS
Everything You Need to Know About FDA’s Priority Review Vouchers
13 Feb 2019 //
RAPS
Teva Receives Positive CHMP Opinion for AJOVY® (fremanezumab) for Migraine
04 Feb 2019 //
BUSINESSWIRE
EMA’s CHMP Recommends 6 New Meds, Releases Outcome of Sartan Investigation
01 Feb 2019 //
RAPS
